Purchase Order 75N91018P00292

Vivitide LLC, doing business as New England Peptide, received a firm fixed-price BPA (Blanket Purchase Agreement) call award from the National Cancer Institute valued at $3,825 on July 12, 2016, with a completion date of July 30, 2016. The contract was performed in Gardner, Massachusetts, and no set-aside designation was utilized. This award represents a task order or purchase call against an existing blanket purchase agreement vehicle, reflecting the National Cancer Institute's continued...

<p>The National Cancer Institute awarded a purchase order to Karebay Biochem Inc. for $22,000 on September 11, 2017, with an ultimate completion date of October 11, 2017. Place of performance is Bethesda, Maryland. The order is for custom organic chemical synthesis and specialized peptide synthesis services in support of cancer research.</p>

This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Vivitide LLC, a manufacturer of laboratory supplies and peptides. The $8,250.00 contract is for the delivery of 96 crude peptides per plate in a 96-well single tube format. The award was not set aside for any specific business category. Vivitide LLC, also doing business as New England Pepdite, has previously...

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $132,000 firm fixed price purchase order to JPT Peptide Technologies GMBH. The contract calls for JPT to design, synthesize, purify, analyze, pool, and test overlapping peptides of the rabies envelope glycoprotein and HPV16 capsid L1 protein. These peptides will be used by NCI's Laboratory of Cellular Oncology to evaluate the potential of viral peptide libraries for cancer treatment. Key...

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for peptide services on August 29, 2017, with a ceiling value of $4,265.34. Work is performed in San Diego, California. The order carries firm fixed price pricing and concludes September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,597.96 on August 29, 2017, for peptide services. Work is performed in San Diego, California. The order is firm fixed price with an ultimate completion date of September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,633.62 on August 22, 2017. The order is for peptide services and carries no set-aside designation. Work is performed in Piscataway, New Jersey. The purchase order is firm fixed price and concludes September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for peptide services valued at $7,701.00 on July 11, 2017. Place of performance is Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of August 9, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,567.96 on August 11, 2017, for peptide services. Work is performed at the awardee's facility in Piscataway, New Jersey. The order is firm fixed price and carries a completion date of September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Polypeptide Laboratories San Diego, LLC for $24,000 on January 16, 2020. The order procures an API (Active Pharmaceutical Ingredient) required for yearly stability testing of material needed to manufacture vaccines for patient treatment. Performance is at Bethesda, Maryland. The contract is firm fixed price with an ultimate completion date of July 15, 2020.</p>